No effects of nirmatrelvir/ritonavir on darunavir plasma trough concentrations: a case report.
Dario CattaneoSimone PaganoSamuel LazzarinNunziata CalvagnaCristina GervasoniPublished in: European journal of hospital pharmacy : science and practice (2024)
COVID-19 may be associated with worst outcomes in people living with HIV compared with HIV-negative patients. Nirmatrelvir/ritonavir can be safely co-administered with all the HIV antiretroviral drugs, without considering dose adjustment. However, no studies have formally investigated the effect of a double booster (ritonavir plus cobicistat) regimen on darunavir concentrations. We presented a case describing the lack of effects of adding nirmatrelvir/ritonavir on darunavir plasma trough concentrations in a patient with HIV already on treatment with a booster-based antiretroviral regimen. We believe this could be a reassuring message for physicians, allowing them to prevent unnecessary denial of COVID-19 treatment or inappropriate discontinuation of co-medications in patients with HIV.
Keyphrases
- antiretroviral therapy
- hiv infected patients
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- sars cov
- coronavirus disease
- hiv testing
- men who have sex with men
- hepatitis c virus
- end stage renal disease
- chronic kidney disease
- primary care
- south africa
- newly diagnosed
- ejection fraction
- high resolution
- respiratory syndrome coronavirus
- patient reported outcomes
- single molecule